Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy

• Published in: Frontiers in oncology Vol. 11; p. 673199
• Main Authors: Guo, Wenwen, Zhang, Caiqin, Qiao, Tianyun, Zhao, Jumei, Shi, Changhong
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29-04-2021
• Subjects: combination therapy; humanized immune system; immunotherapy; mouse model; Oncology; tumor; combination therapy; mouse model; tumor; immunotherapy; humanized immune system
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.673199

Immunotherapy has been used as a first-line treatment for a variety of advanced tumors, allowing remarkable progress to be made in cancer treatment. Nonetheless, only a small number of patients can benefit from immune checkpoint inhibitor monotherapy. To improve the effect of immunotherapy, the underlying mechanism of combination therapy was investigated in the context of an intact human tumor immune microenvironment using mice with a human immune system (HIS) bearing human tumors. Herein, we summarize and discuss strategies for the development and use of HIS mice models in tumor immunotherapies. Most importantly, this review proposes a method of t11umor identification and classification in HIS mice based on the tumor-infiltrating lymphocytes and PD-L1 expression, and according to this classification, we propose different combination treatment strategies that can be utilized to enhance the effect of immunotherapy. Thus, we provide effective experimental schemes for tumor immunotherapy in HIS mice models.